Successful treatment of severe psoriasis with basiliximab, an interleukin-2 receptor monoclonal antibody

Clinical and Experimental Dermatology

Volumn 25, Issue 3, 2000, Pages 195-197

  Owen, C M ^a   Harrison, P V ^b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; FLUOXETINE; INTERLEUKIN 2 RECEPTOR ANTIBODY; METHOTREXATE; PSORALEN; SEROTONIN UPTAKE INHIBITOR; TACROLIMUS;

ADULT; ARTICLE; CASE REPORT; CELLULAR IMMUNITY; DISEASE COURSE; DISEASE SEVERITY; DRUG MECHANISM; FEMALE; HUMAN; PRIORITY JOURNAL; PSORIASIS; REMISSION; ULTRAVIOLET A RADIATION;

ANTIBODIES, MONOCLONAL; CYCLOSPORINE; DERMATOLOGIC AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MIDDLE AGED; PSORIASIS; RECEPTORS, INTERLEUKIN-2; RECOMBINANT FUSION PROTEINS; TREATMENT OUTCOME;

EID: 0034074077     PISSN: 03076938     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2230.2000.00612.x     Document Type: Article

References (9)

1. 1 Valdimarsson H, Baker BS, Jonsdottir I et al. Psoriasis: a T-cell-mediated autoimmune disease induced by streptococcal superantigens? Immunol Today 1995; 16: 145-9.
2. 2 Uyemura K, Yamamura M, Fivenson DF et al. The cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helper type 1 cell-mediated response. J Invest Dermatol 1993; 101: 701-5.
3. 3 De Rie MA, Zonneveld IM, Witkamp L et al. Soluble interleukin-2 receptor (sIL-2R) is a marker of disease activity in psoriasis: a comparison of sIL-2R, sCD27, sCD4, sCD8 and sICAM-1. Acta Dermatol Venereol 1996; 76: 357-60.
4. 4 Lee RE, Gaspari AA, Lotze MT et al. Interleukin 2 and psoriasis. Arch Dermatol 1998; 124: 1811-5.
5. 5 Gottlieb SL, Gilleaudeau P, Johnson R et al. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nature Med 1995; 1: 442-7.
6. 6 Bagel J, Garland WT, Breneman D et al. Administration of DAB389IL-2 to patients with recalcitrant psoriasis: a double-blind, phase II muticenter trial. J Am Acad Dermatol 1998; 38: 938-44.
7. 7 Nashan B, Moore R, Amlot P et al. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. Lancet 1997; 350: 1193-8.
8. 8 Kovarik J, Wolf P, Cisterne JM et al. Disposition of basiliximab, an interleukin-2 receptor monoclonal antibody, in recipients of mismatched cadaver renal allografts. Transplantation 1997; 64: 1701-5.
9. 9 Hemlock C, Rosenthal JS, Winston A. Fluoxetine-induced psoriasis. Ann Pharmacother 1992; 26: 211-2.